Novo Nordisk: Stock Plunges, But It May Be Time To Load Up
Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...
Roche takes big step in weight-loss field with $5.3 billion deal. Novo Nordisk shares fall.
Swiss drugmaker Roche on Wednesday announced a major deal in the weight-loss category, agreeing to pay up to $5.3 billion to Zealand Pharma in a licensing and development agreement. Zealand Pharma's ...
BioSpace3d
COVID Reflections, Novo’s Next-Gen Weight Loss Struggles, Another Depression Miss, More
BioSpace remembers COVID-19 five years after the pandemic was declared, Novo Nordisk’s CagriSema again misses expectations as the company joins a lawsuit filed by drug compounders against the FDA, ...
Medical Marketing & Media4d
Novo Nordisk welcomes patients to the Ozempic Era
With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.
Data on new Novo Nordisk obesity drug disappoints in trial, shares drop
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...
Novo Nordisk Shares Fall After Latest CagriSema Obesity Drug Trial Results
New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an ...
Novo Nordisk (NVO) Sinks after Weight-Loss Drug Trial Misses Expectations
Shares of Novo Nordisk’s (NVO) are down over 9% at the time of writing after the company announced the results from its latest weight-loss drug ...
Roche Hires Novo Executive to Help Push Into Obesity Drug Market
Roche Holding AG hired a senior executive from rival Novo Nordisk A/S as the Swiss drugmaker prepares to enter the ...
Zacks Investment Research on MSN10d
Novo Nordisk Plunges 21% in 3 Months: Buy, Sell or Hold the Stock?
Novo Nordisk NVO shares have lost 21% in the past three months against the industry’s growth of 4.6%. The company has also ...
manilatimes16d
Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S
Also, Novo Nordisk offers the possibility of viewing the Annual General Meeting via live webcast on Novo Nordisk's website. Please refer to the enclosed notice for the Annual General Meeting for ...
NJBIZ18d
Drug compounders sue FDA over Novo Nordisk’s Ozempic, Wegovy (updated)
Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug Wegovy and diabetes treatment Ozempic without a fight. An industry group ...
MarketWatch18d
Novo Nordisk shares are rallying as Hims & Hers’ stock falters. An Ozempic alternative won’t be available for long.
Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much longer. Hims & Hers Health Inc.’s stock plunged last week when the ...